MEENAKSHI ANURAG to Triple Negative Breast Neoplasms
This is a "connection" page, showing publications MEENAKSHI ANURAG has written about Triple Negative Breast Neoplasms.
Connection Strength
1.367
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
Score: 0.588
-
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2025 Nov 03; 15(11):2326-2343.
Score: 0.181
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 03 01; 10(3):362-371.
Score: 0.161
-
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 08; 3(8):1551-1563.
Score: 0.155
-
Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer. Sci Rep. 2022 10 22; 12(1):17732.
Score: 0.147
-
Immunogenomic?profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Aug; 189(1):187-202.
Score: 0.134